520 results on '"Burge, Russel"'
Search Results
102. Ixekizumab treatment patterns and healthcare utilization and costs for patients with psoriasis
103. Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses
104. Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis
105. Ixekizumab treatment patterns and healthcare utilization and costs for patients with psoriasis
106. The marginal practice cost of physicians' services
107. Methodology for Estimating Current and Future Burden of Osteoporosis in State Populations: Application to Florida in 2000 through 2025
108. Inpatient Hospital and Post-Acute Care for Vertebral Fractures in Women
109. Tibia shaft fractures: costly burden of nonunions
110. Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review
111. Additional file 1: of Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization
112. Development of the Psoriasis Symptoms Scale (PSS) in patients with moderate-to-severe psoriasis: qualitative and quantitative analyses
113. Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial
114. Burden and Disease Characteristics of Patients with Psoriatic Arthritis: A Population-based Cross-sectional Study
115. Study description and baseline characteristics of the population enrolled in a multinational, observational study of teriparatide in postmenopausal women with osteoporosis: the Asia and Latin America Fracture Observational Study (ALAFOS)
116. The experience of itch in children with psoriasis: A qualitative exploration of the Itch Numeric Rating Scale.
117. Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses.
118. Ixekizumab treatment patterns and healthcare utilization and costs for patients with psoriasis.
119. 26654 Ixekizumab demonstrates greater medication adherence, persistence, and longer monotherapy duration than secukinumab, adalimumab, ustekinumab, and etanercept up to 3 years in the treatment of psoriasis: Real-world results
120. Diffusion of Medicare's RBRVS and related physician payment policies
121. Allocating practice expense under the Medicare fee schedule
122. Development of the Psoriasis Symptoms Scale (PSS) in patients with moderate-to-severe psoriasis: qualitative and quantitative analyses.
123. Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial.
124. Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.
125. Ixekizumab Results in Persistent Clinical Improvement in Moderateto-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial.
126. Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis
127. Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis
128. The Development of the Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) to Assess the Impact of Genital Psoriasis on Sexual Health
129. The Development of a Patient-Reported Outcome Measure for Assessment of Genital Psoriasis Symptoms: The Genital Psoriasis Symptoms Scale (GPSS)
130. Examining the Effect of Medication Adherence on Risk of Subsequent Fracture Among Women with a Fragility Fracture in the U.S. Medicare Population
131. Efficacy, Health-Related Outcomes, and Safety of Ixekizumamb for up to Five Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis
132. Additional file 1: Figure S1. of Interpreting change from patient reported outcome (PRO) endpoints: patient global ratings of concept versus patient global ratings of change, a case study among osteoporosis patients
133. Understanding characteristics of patients newly initiating ixekizumab: findings from the Corrona Psoriasis Registry
134. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis
135. Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia)
136. Interpreting change from patient reported outcome (PRO) endpoints: patient global ratings of concept versus patient global ratings of change, a case study among osteoporosis patients
137. Real-world clinical and economic outcomes for daily teriparatide patients in Japan
138. Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension.
139. Inpatient cost of treating osteoporotic fractures in mainland China: a descriptive analysis
140. Clinical and Economic Characteristics of Total Hip Replacement Patients with High Health Care Costs and High Health Care Use
141. Can Bundled Payment Improve Quality and Efficiency of Care for Patients with Hip Fractures?
142. Posthospital Discharge Medical Care Costs and Family Burden Associated with Osteoporotic Fracture Patients in China from 2011 to 2013
143. Psychometric properties of the osteoporosis assessment questionnaire (OPAQ) 2.0: results from the multiple outcomes of raloxifene evaluation (MORE) study
144. Characteristics of hip fracture patients with and without muscle atrophy/weakness: Predictors of negative economic outcomes
145. 302: Glycemic Effect of Extended-Release Niacin Plus Statin versus Other Lipid Therapies in Managed Care Dyslipidemia Patients with Type 2 Diabetes
146. Retrospective database study to assess the economic impact of hip fracture in the United Kingdom
147. Fractures in women treated with raloxifene or alendronate: a retrospective database analysis
148. Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study
149. Use of health-related quality of life measures to predict health utility in postmenopausal osteoporotic women: results from the Multiple Outcomes of Raloxifene Evaluation study
150. Adherence and Persistence with Once-Daily Teriparatide in Japan: A Retrospective, Prescription Database, Cohort Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.